

Whole Genome Sequencing in Personalized Oncology

V Retèl(1), W van Harten(1), M Joore(2), M IJzerman(3), H Koffijberg(3), V Coupé(4), G Frederix(5), T Feenstra(6), C Uyl(7), I Eekhout(1), M van de Vijver(8), J Aerts(9), A van den Eertwegh(4), E Smit(1), S Sleijfer(9), E Voest(1), M Ploem(8), S Gevers(8), A Bredenoord(5), R Butter(8), C Pasmans(5), M Simons(2), M van de Ven(3), D Hurkmans(9), N Giesbertz(5), C Mitchell(8), E Cuppen(5)

(1)Netherlands Cancer Institute; (2)Maastricht University Medical Center; (3)University of Twente; (4)VU Medical Center; (5)University Medical Center Utrecht; (6) University Medical Center Groningen; (7) Erasmus University; (8)Academic Medical Center; (9) Erasmus Medical Center


RATIONALE

- Large variability between Next Generation Sequencing (NGS) tests throughout laboratories in the Netherlands.
- Increasing application of immunotherapy, while only a selected group will benefit: need for biomarker
- Consequence: ↓quality of life due to side effects and ↑healthcare costs.
- **How can we apply NGS to select patients who will benefit from immuno- or targeted therapy?**


GOALS

- To expand **molecular profiling** of tumors in order to improve **immune- and targeted treatment selection** and outcomes in patients with advanced melanoma and NSCLC . **WP: 1,2,3**
- To project long-term **cost-effectiveness, budget impact**, and relevant **patient, organizational & legal issues** related to the introduction of WGS compared to standard diagnostics. **WP: 4,5,6**

DATAFLOW



WORKFLOW



RELEVANCE TO HEALTH-RI

- Project aimed at improving personalized oncology
- Storage of large amounts of biological data in a biobank
- FAIR handling of biological data
- Nationwide organization of reporting molecular data

